top of page

Pioneering novel immunotherapies
through AI-led TCR & antibody design

Powered by cutting-edge drug discovery AI & EXPERIMENTAL validation

PARTNERED WITH

Nvidia-Horizontal-Black-Logo2.png
Google-Logo.black2.png
VECTOR labs - black.png
Imperial_College_London_black.png

OUR MISSION

Pioneer the combination of machine and human intelligence to develop the best immunotherapies for cancer patients in urgent need

3

TCR and Antibody specific LLMs fine-tuned/created

3

Pipeline programmes

6

In silico design to lead candidates in six months

HOW CAN WE HELP YOU?

Elevate your drug discovery outcomes.
 

We deliver safer, more precise drug candidates for your pipeline – faster.

How it works

Rapid design & engineering of new candidates and biobetters

Unlock the full potential of your research with EMLy Co-pilot & LLMs

Industry-first TCR and antibody-specific LLMs connected to EMLy co-pilot, empowering scientists with cutting-edge informatics & insights.

Discover how we identify novel targets and therapeutics through the Long term Cancer Survivor Program

Leverage our unmatched scale in deep sequencing, enhanced by EMLy AI error correction, to boost immune repertoire accuracy and align with our exclusive proprietary databases.

 

Discover how we identify our next target through the Long Term Survivor Programme.